Navigation Links
Diabetes drug shows promise in fighting lethal cancer complication
Date:9/24/2009

COLUMBUS, Ohio Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research.

And in an animal study, a diabetes drug that promotes insulin sensitivity slowed the progression of muscle wasting and fat loss, the main consequences of a syndrome called cachexia, in mice with colon cancer tumors.

Though it remains unknown whether that drug, rosiglitazone, has potential to prevent cachexia in humans with cancer, the finding led researchers to believe that curbing insulin resistance in cancer patients could improve their quality of life.

Research suggests that cachexia is responsible for between one-fifth and one-third of all cancer deaths.

The insulin resistance and cachexia both appear to be connected to inflammation induced either by tumors themselves or by secretions from tumors that activate an immune response, the researchers say.

"Insulin resistance usually follows obesity. In this case, it precedes uncontrollable fat loss," said Martha Belury, senior author of the study and a professor of human nutrition at Ohio State University. "The insulin resistance is the process we've identified that occurs soon after tumors form. So if we can change that part of the disease, we might be able to change the progression and trajectory of how fast fat and muscle are lost as well. That's our goal."

The research appears online and is scheduled for future print publication in the International Journal of Cancer.

Belury and colleagues conducted two experiments. In the first, the researchers sought to demonstrate that animals developed insulin resistance shortly after they developed cancer and before muscle and fat loss became evident. In the second, they tested the effectiveness of the insulin sensitizing drug rosiglitazone again
'/>"/>

Contact: Martha Belury
belury.1@osu.edu
614-292-1680
Ohio State University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. 1 million euro EU grant for MDC diabetes researcher Dr. Francesca M. Spagnoli
2. Diabetes drug kills cancer stem cells in combination treatment in mice
3. Size of fat cells and waist size predict type 2 diabetes in women
4. Medicine wheel model for nutrition shows promise for control of type 2 diabetes
5. JDRF-funded studies show regular CGM use increases diabetes control for all age groups
6. Scientists discover new genetic variation that contributes to diabetes
7. Diabetes advance: Researchers find gene that causes resistance to insulin
8. DNA mutations linked to diabetes
9. UCF discovery could open door to obesity, diabetes treatments
10. Stimulus funding helps K-State biochemist study eyes lens in diabetes, galactosemia patients
11. Common allergy drug reduces obesity and diabetes in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need ... your password, site key or the answer to your secret ... teacher? Today, Hoyos Labs , a ... will finally put an end to the frustration that comes ... . 1U leverages a user,s smartphone to acquire his or ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... Health announced today that it will fund 22 grants ... modifications to genes that result from diet, aging, stress, ... human diseases and biological processes. The awards ... of the NIH Roadmap for Medical Research,s Epigenomics Program. ...
... Prevention Institute at Kansas State University is being honored ... Prevention Roundtable. The K-State institute,s intern program has ... award, also called the MVP2 award, as the best ... Sept. 22, in Washington, D.C. The award is ...
... Calif., September 15, 2009 -- Researchers at the ... that reactive oxygen species, such as superoxide and ... invadopodia, cellular protrusions implicated in cancer cell migration ... director of the Tumor Microenvironment Program at Burnham,s ...
Cached Biology News:NIH funds grantees focusing on epigenomics of human health and disease 2NIH funds grantees focusing on epigenomics of human health and disease 3NIH funds grantees focusing on epigenomics of human health and disease 4K-State Pollution Prevention Institute's intern program named best 2Reactive oxygen's role in metastasis 2
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
(Date:12/19/2014)... Arlington, MA (PRWEB) December 18, 2014 ... products for ophthalmology and wound care. The National Eye ... has awarded LayerBio a Phase I SBIR grant to ... , Cataracts are the most common cause of vision ... cause of blindness worldwide. According to Dr. Ken Mandell, ...
(Date:12/19/2014)... The empty capsules market is experiencing growth primarily ... innovations in the empty capsules market. The fast-growing ... of the empty capsules market. , Get Full ... Report , The report will enrich both established ... gauge the pulse of the market which in ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
Breaking Biology Technology:Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... TEL-AVIV, Israel, October 17 TopSpin Medical,(TASE: TOPMD), ... MRI,using an IntraVascular MRI (IVMRI) catheter for the ... Ph.D., as Vice President,Clinical Affairs. Dr. Setum ... research in,the medical device industry. She has a ...
... Oct. 17 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... that its lead product candidate, picoplatin,has been granted ... cell lung cancer (SCLC) by the European Commission. ... Committee for Orphan Medicinal,Products (COMP) of the European ...
... GenVault announced today that,the Henry C. Witelson Ocular ... purchased a Personal Archive biosample management system.,The laboratory ... will be a critical component of the Laboratory,s,research ... as uveal,melanoma and retinoblastoma and for developing new ...
Cached Biology Technology:TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs 2Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 2Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 3Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 4McGill University Purchases GenVault's Personal Archive System to Manage Rare Cancer Samples 2
Tissue-Stat ( Tissue Adherent for Mounting Formalin-Fixed and Frozen Tissue Sections.)...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
... Plus is formulated for covering tissue sections and ... soluble OR alcohol insoluble end products. ... as Fast Red or AEC that require an ... such as DAB. No heating is required prior ...
Biology Products: